Merck claims hepatitis C patent win

A US court has upheld the validity of two patents owned by Merck in the pharmaceutical company’s dispute with drug maker Gilead centring on hepatitis C treatments.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Federal Circuit affirms Merck ‘unclean hands’ verdict

26 April 2018 The US Court of Appeals for the Federal Circuit has affirmed a finding that pharmaceutical company Merck had engaged in misconduct and was not allowed to bring an action against Gilead.

Americas

Gilead v Merck hepatitis C dispute rocked by new allegation

3 May 2016 A judge assessing a patent dispute between Merck and Gilead centring on hepatitis C treatments has allowed Gilead to submit new evidence of jurors allegedly being misled.

Americas

Merck handed $200m in Gilead hepatitis C row

29 March 2016 Gilead has been ordered to pay Merck $200 million in damages following a trial that found it had infringed patents covering hepatitis C treatments.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

Merck claims hepatitis C patent win

More on this story

Editor's picks

Editor's picks

More features